Industry Reports
Bayer lifts sales-Grow by 16.1 percent to EUR 8,581 million
The Bayer Group significantly raised sales and underlying earnings in the third quarter of 2010. “We are pleased that our third-quarter results showed an improvement on last year, and we remain confident for the full year 2010,” Management Board...
Industry Reports
ICON reports revenues of $225 million up 2% on prior year
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, reported its financial results for the third quarter ended September 30, 2010. Net revenues for the quarter were $225 million, representing a 2%...
Industry Reports
Pfizer Entering into a partnership with Laboratorio Teuto Brasileiro S.A to develop and commercialize generic medicines
Pfizer Inc. announced that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines. Pfizer will acquire a 40 percent stake in Teuto and...
Industry Reports
Genzyme Reports Financial Results for the Third-quarter revenue was $1.0 billion,
Genzyme Corp. reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so...
Industry Reports
Teva to Report Third Quarter 2010 Financial Results on November 2, 2010
Teva Pharmaceutical Industries Ltd. announced that it will release its third quarter 2010 financial results on Tuesday, November 2, 2010. Teva will host a conference call and live webcast on the same day, at 8:30 a.m....
Industry Reports
Cephalon Reports Record Sales – Quaterly sales increased 32% percent
Cephalon, Inc. reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter 2009. Basic income per common share for the quarter was $1.18. Excluding amortization expense and...
Industry Reports
Ranbaxy Achieves USD 1 Billion Revenue
The Board of Directors of Ranbaxy Laboratories Limited (RLL) at their meeting held today, took on record the unaudited results for the quarter ended June 30, 2010 (the “Quarter”). Key Financial HighlightsFinancial Performance for the quarter...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.